

Date 09/05/2025
Your Ref
Our Ref 10001

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION – ADULT MULTIPLE MYELOMA

I write in response to your request for information in relation to adult multiple myeloma.

Question:

- Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

Answer:

There were 263 patients treated.

Question:

- Of the multiple myeloma patients treated over the past 6 months, how many were treated with the following:

Answer:

a.	Belantamab Mafodotin [Blenrep]	Nil
b.	Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone	Nil
c.	Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone	Nil
d.	Bortezomib [Velcade] monotherapy or with dexamethasone	5<
e.	Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/ dexamethasone (VMp or VCd)	5<
f.	Bortezomib, thalidomide and dexamethasone [VTD]	Nil
g.	Carfilzomib [Kyprolis] and dexamethasone	9
h.	Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone	5<
i.	Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	47
j.	Daratumumab [Darzalex] monotherapy	19
k.	Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	34
l.	Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)	27

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common
name of Lothian Health Board

m.	Elranatamab	6
n.	Idecabtagene vicleucel [Abecma]	Nil
o.	Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)	6
p.	Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)	Nil
q.	Lenalidomide [Revlimid] and dexamethasone	65
r.	Lenalidomide [Revlimid] monotherapy	48
s.	Panobinostat in combination with Bortezomib and Dezamethasone	Nil
t.	Pomalidomide [Imnovid] and dexamethasone	14
u.	Selinexor and dexamethasone	Nil
v.	Selinexor, Bortezomiv [Velcade] and dexamethasone	Nil
w.	Talquetamab	Nil
x.	Teclistamab [Tecvayli]	Nil
y.	Any other systemic anti-cancer therapy	14

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive